The association of night-time systolic blood pressure with ultrasound markers of subclinical cardiac and vascular disease by O'Flynn, Anne Marie et al.
Title The association of night-time systolic blood pressure with ultrasound
markers of subclinical cardiac and vascular disease
Author(s) O'Flynn, Anne Marie; Ho, Emily; Dolan, Eamon; Curtin, Ronan J.;
Kearney, Patricia M.
Publication date 2017
Original citation O’Flynn, A. M., Ho, E., Dolan, E., Curtin, R. J. and Kearney, P. M.
(2017) 'The association of night-time systolic blood pressure with
ultrasound markers of subclinical cardiac and vascular disease', Blood
Pressure Monitoring, 22(1), pp. 18-26. doi:
10.1097/MBP.0000000000000223
Type of publication Article (peer-reviewed)
Link to publisher's
version
https://journals.lww.com/bpmonitoring/Fulltext/2017/02000/The_associ
ation_of_night_time_systolic_blood.4.aspx
http://dx.doi.org/10.1097/MBP.0000000000000223
Access to the full text of the published version may require a
subscription.
Rights © 2017, the Authors. This is an open-access article distributed under
the terms of the Creative Commons Attribution-Non Commercial-
No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible
to download and share the work provided it is properly cited. The
work cannot be changed in any way or used commercially without
permission from the journal.
http://creativecommons.org/licenses/by-nc-nd/4.0/
https://creativecommons.org/licenses/by-nc-nd/4.0/
Item downloaded
from
http://hdl.handle.net/10468/6342
Downloaded on 2019-01-07T05:57:23Z
D
ow
nloaded
from
https://journals.lw
w
.com
/bpm
onitoring
by
B
hD
M
f5eP
H
K
av1zE
oum
1tQ
fN
4a+kJLhE
ZgbsIH
o4X
M
i0hC
yw
C
X
1A
W
nY
Q
p/IlQ
rH
D
33gD
m
upaxC
Iw
v+D
nK
cfg29d2LbxA
O
8Tqj7A
ID
8fR
IxY
I/zD
N
P
FA
7S
8g==
on
06/07/2018
Downloadedfromhttps://journals.lww.com/bpmonitoringbyBhDMf5ePHKav1zEoum1tQfN4a+kJLhEZgbsIHo4XMi0hCywCX1AWnYQp/IlQrHD33gDmupaxCIwv+DnKcfg29d2LbxAO8Tqj7AID8fRIxYI/zDNPFA7S8g==on06/07/2018
The association of night-time systolic blood pressure with
ultrasound markers of subclinical cardiac and vascular
disease
Anne Marie O’Flynna, Emily Hod, Eamon Dolanc, Ronan J. Curtinb and
Patricia M. Kearneya
Introduction The aim of this study was to examine the
association of night-time systolic blood pressure (BP) with
subclinical cardiac dysfunction measured by global
longitudinal strain (GLS) and subclinical vascular damage
measured by carotid intima–media thickness (CIMT) and
carotid plaques.
Methods GLS was measured by speckle-tracking analysis
of echocardiogram images. CIMT was measured at the
distal 1 cm of the common carotid artery. The presence of
carotid plaques was recorded. Philips QLAB cardiac and
vascular ultrasound quantification software was used for
analysis. The association of night-time systolic BP with
GLS, CIMT and carotid plaques was assessed using linear
and logistic regression.
Results Fifty (response rate 63%) individuals took part in
this study. In univariable models, night-time systolic BP was
significantly associated with GLS [β coefficient 0.85 for
every 10mmHg increase, 95% confidence interval (CI):
0.3–1.4] and carotid plaques (odds ratio 1.9 for every
10mmHg increase, 95% CI: 1.1–3.2). Univariable analysis of
daytime systolic BP did not show any statistically significant
associations. In age-adjusted and sex-adjusted models, the
association for night-time systolic BP and GLS remained
significant (β coefficient 0.68 for every 10mmHg increase,
95% CI: 0.1–1.3). The association for carotid plaques was no
longer statistically significant. In multivariable models,
findings were diminished.
Discussion Our results suggest a trend towards an
association between night-time systolic BP and subclinical
cardiac and vascular disease. When assessing ambulatory
blood pressure monitoring results, the absolute night-time
systolic BP seems to be a better prognostic parameter than
daytime systolic BP, but ultimately a large randomised
controlled trial involving chronotherapy is necessary to fully
address this. Blood Press Monit 22:18–26 Copyright © 2017
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Cardiovascular disease remains the leading cause of
mortality worldwide [1] and hypertension is the risk
factor with the greatest population-attributable risk [2,3].
Prevalence rates of hypertension are high, whereas con-
trol rates are low [4]. Ambulatory blood pressure mon-
itoring (ABPM) measures blood pressure (BP) over
24–48 h and has been shown to be superior to office BP
for the prediction of clinical events [5,6]. Night-time
systolic BP is a stronger predictor of events than daytime
systolic BP [7].
Although it is unclear whether night-time BP should be a
specific therapeutic target, chronotherapy has shown
some promising results. In one study, patients were
randomized to either take all of their antihypertensive
medications in the morning or to take at least one of them
at night. The decrease in nocturnal BP was associated
with a reduced risk of total cardiovascular events.
Similarly, patients with chronic kidney disease who took
at least one antihypertensive at night had a lower hazard
ratio of total cardiovascular events than those taking all of
their medications in the morning [8,9].
The association of night-time BP with subclinical target
organ damage has been investigated [10,11]. This would
seem intuitive, given the greater association of night-time
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal's website (www.bpmonitoring.com).
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permission from the journal.
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BP with clinical events, the continuum of cardiovascular
disease [12] and subclinical disease being a prognostic
marker for future cardiovascular events [13]. Many stu-
dies have focused on dipping status rather than the
absolute BP level [14–16]. We have previously shown
that absolute night-time systolic BP is better associated
than dipping status with subclinical cardiac and vascular
damage documented by electrocardiogram left ven-
tricular hypertrophy (LVH) voltage criteria and micro-
albuminura in the Mitchelstown Cohort Study [17].
Echocardiography can measure the subclinical cardiac
consequences of hypertension such as increased left atrial
(LA) size and LVH. Speckle-tracking echocardiography
has enabled the quantification of strain, which is a
dimensionless measure of myocardial deformation.
Global longitudinal strain (GLS) is a measure of the
myocardial systolic deformation over the longitudinal axis
[18]. There is emerging evidence for the prognostic
importance of this measure [19,20]. It offers incremental
prognostic information in the assessment of left ven-
tricular (LV) function, particularly when the ejection
fraction is near normal [21]. Few studies have examined
the association of night-time BP and GLS measured by
speckle-tracking analysis [22,23].
Carotid intima–media thickness (CIMT) measured by
ultrasound is a marker of subclinical vascular damage and
is recognized to be associated with cardiovascular risk
factors and with the incidence of myocardial infarction
and stroke [24,25]. There is evidence for the validity of
CIMT as a suitable surrogate measure of atherosclerotic
disease [26,27]. The addition of carotid plaques to risk
prediction models including CIMT improves perfor-
mance [28,29].
The present study aims to build on previous work by
examining the association of night-time systolic BP with
ultrasound markers of subclinical cardiovascular disease
including abnormal GLS, CIMT and carotid plaques in a
sample from the Mitchelstown Cohort Study.
Methods
In 2010, the Mitchelstown Cohort Study recruited 2047
participants from a single large primary care centre, the
Livinghealth Clinic in Mitchelstown, a town in the south
of Ireland [30]. Of these, 1207 (response rate 59%) also
underwent 24-h ABPM. These individuals provide the
sample for the present study. On the basis of the initial
ABPM results, the sample was divided into four groups:
normotension, isolated nocturnal hypertension, isolated
daytime hypertension and day–night hypertension.
Twenty participants were selected randomly from each
group and invited to attend for echocardiogram and car-
otid ultrasound in 2014. This study therefore includes
analysis of baseline ABPM data and follow-up
imaging data.
Height and weight measurements
A trained researcher carried out the physical measures.
Height and weight were measured without footwear using
a Seca (Hamburg, Germany) measuring and weighing
station. BMI and body surface area (BSA) were calculated.
Study blood pressure
At the baseline visit after the participant had been in a
relaxed seated position for at least 5 min, three BP
readings were taken on the right arm, 1 min apart, using
an OMRON M7 digital automatic BP monitor (OMRON
Healthcare Europe B.V., Hoofddorp, the Netherlands).
The average of the second and third BP reading was
defined as the study BP.
Ambulatory blood pressure monitoring
ABPM measurements were performed at baseline using
the MEDITECH (Budapest, Hungary) ABPM-05 and
data were stored using the dabl ABPM system (dabl Ltd,
Dublin, Ireland). The monitors were programmed to
record the BP every 30 min throughout the 24-h period.
Participants kept a diary of the times they went to bed
and got up. Diary times were used to calculate the mean
daytime and night-time BP. The mean 24-h BP was
calculated as the mean of all the readings throughout the
24-h period.
Echocardiography
A Philips iE33 ultrasound machine (Philips Healthcare,
Guildford, UK) and a S5-1 phased array transducer were
used for image acquisition. All scans were carried out by the
same operator (I.B.). I.B. is accredited in transthoracic echo-
cardiography by the British Society of Echocardiography. A
standard echocardiogram protocol was used. Parasternal long
and short axis, apical four-chamber, two-chamber and three-
chamber views were obtained. Optimization of frame rate
was carried out by reducing the sector depth and width.
LV wall thickness and diameters were measured from the
parasternal long axis view. LV mass was calculated using
the Devereux formula [31]. LV mass was indexed for
BSA. LVH was defined as LV mass more than 115 g/m2
in men and more than 95 g/m2 in women [32]. LV
volumes and ejection fraction were calculated from the
apical four-chamber view using the single-plane method
of discs [33]. LV volumes were indexed for BSA. LA
volume was calculated from the apical four-chamber view
using the single-plane method of discs. LA volume was
indexed for BSA [32].
Diastolic function parameters were measured in the
apical four-chamber view. Mitral inflow early (E) and late
(A) velocities and E wave deceleration time were
obtained by pulse-wave Doppler with the sample volume
at the mitral valve tips. Peak diastolic mitral annular (e′)
velocity was measured from the septal and lateral mitral
annulus and averaged. The E/e′ ratio was then calculated.
Diastolic dysfunction was defined as E/A≤ 0.7 or
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deceleration time > 260 ms; or E/A> 0.7 and ≤ 1.5 and
e′ velocity < 7 cm/s; or E/A> 1.5 and e′ velocity < 7 cm/s
or deceleration time < 140 ms [34].
The acquired images were saved using digital media and
speckle-tracking GLS analysis was carried out offline by a
single reader (A.M.O.F.) from apical four-chamber, two-
chamber and three-chamber views using Philips QLAB
cardiac and vascular ultrasound quantification software
(version 9.0; Philips). The region of interest was identi-
fied by the selection of three points, one on either side of
the mitral valve annulus and one at the apex for each
view. Adequate tracking was confirmed visually and, if
deemed inadequate, the region of interest was edited. If
inadequate tracking persisted, problematic segments
were excluded. If more than two segments in a single
view had to be excluded, the entire study was excluded
from speckle-tracking analysis [32]. GLS average was
obtained from 17 ventricular segments represented on a
bulls-eye plot from these views. Normal cut-off was
taken as − 19.7% [35].
Carotid ultrasound
A Philips Cx50 portable ultrasound machine and an L12-
3 linear array transducer were used for image acquisition.
All scans were carried out by the same operator (A.M.O.
F.). A.M.O.F. received formal training in CIMT image
acquisition. Patients were examined in the supine posi-
tion with their head tilted to the opposite side. A Meijer
arc was used to ensure optimal positioning. A thorough
transverse and longitudinal scan of the extracranial car-
otid arteries was carried out to evaluate for the presence
of atherosclerotic plaques. Ultrasound images of the
distal portion of the far wall of both common carotid
arteries were obtained for assessment of CIMT. Far-wall
still frames were taken from anterior, lateral and posterior
angles. Three still frame images were taken from each
angle [36].
The acquired images were saved using digital media and
measurement was carried out offline by a single reader
(A.M.O.F.) using Philips QLAB cardiac and vascular
ultrasound quantification software (version 9.0; Philips).
Measurements were made on the three still frame images
from each angle over a length of 1 cm at the distal com-
mon carotid artery (CCA). The reference point for the
commencement of the measurement was where the CCA
began to dilate before the bifurcation. A mean mea-
surement from each angle was obtained. The mean of
these means was obtained to yield the measurement for
each side. The mean of the left and right was then taken
as the CIMT. Normal cut-off was taken as the 75th
percentile [37]. The presence of plaques in the extra-
cranial carotid arteries was recorded as a binary variable. A
plaque was defined according to the Mannheim
Consensus as a focal protrusion into the blood vessel of at
least 50% of the thickness of the adjacent IMT or focal
IMT more than 1.5 mm [38].
Reproducibility
Intraobserver and interobserver reproducibility was
assessed before carrying out the study. Ten patients
undergoing routinely indicated echocardiography were
asked to consent to have their images analysed by
speckle-tracking analysis. All echocardiograms were car-
ried out by the same operator (I.B.). Speckle-tracking
analysis was carried out offline by A.M.O.F. and repeated
for intraobserver reproducibility. An independent obser-
ver (E.H.) also analysed the images for interobserver
reproducibility. Ten healthy volunteers underwent a
carotid ultrasound twice within the same week carried
out by the same investigator (A.M.O.F.), who also ana-
lysed the images for intraobserver reproducibility. An
independent observer (E.H.) analysed the second set of
images for interobserver reproducibility.
The intraobserver intraclass coefficient (ICC) for GLS was
0.93 [95% confidence interval (CI): 0.70–0.98]. The
interobserver ICC was 0.86 (95% CI: 0.51–0.96). The
intraobserver ICC for CIMTwas 0.91 (95% CI: 0.69–0.98).
The interobserver ICC was 0.97 (95% CI: 0.88–0.99).
Statistical analysis
Statistical analysis was carried out using Stata 12
(StataCorp LP, College Station, Texas, USA). Continuous
variables are described by mean±SD. Categorical vari-
ables are described using proportions. Univariable linear
and logistic regression analysis was used to compare
echocardiographic and carotid ultrasound findings between
groups.
The association of baseline night-time, daytime and
study systolic BP with GLS and CIMT was assessed
using univariable and multivariable linear regression.
The association of baseline night-time, daytime and
study systolic BP with carotid plaques was assessed using
logistic regression. Regression models were initially
adjusted for sex and age. Multivariable regression ana-
lysis was also carried out with adjustments applied for
sex, age, BMI, smoking status, diabetes mellitus and total
cholesterol. Interaction terms including antihypertensive
medications with night-time, daytime and study systolic
BPs, respectively, were also included in the models.
Ethical considerations
The study was approved by the Clinical Research Ethics
Committee of the Cork Teaching Hospitals and was
carried out in accordance with the Declaration of
Helsinki. All participants provided informed consent.
Results
Fifty (overall response rate 63%) individuals took part in
this study. The mean period of follow-up was 3.9 years.
The mean age of the participants was 60 years and 26
(52%) were men. Baseline characteristics are presented in
Table 1, together with the baseline characteristics of the
full cohort and those who underwent ABPM.
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The echocardiogram and carotid ultrasound findings by
BP strata are presented in Table 2. Speckle-tracking
echocardiography analysis was not possible in one study
because of poor image quality. In univariable models,
night-time systolic BP was significantly associated with
GLS (β coefficient 0.85 for every 10 mmHg increase, 95%
CI: 0.3–1.4) and carotid plaques (odds ratio 1.9 for every
10 mmHg increase, 95% CI: 1.1–3.2). Univariable analy-
sis of daytime systolic BP did not show any statistically
significant associations (Table 3). In age-adjusted and
sex-adjusted models, the association for night-time sys-
tolic BP and GLS remained significant (β coefficient 0.68
for every 10 mmHg increase, 95% CI: 0.11–1.25). The
association for carotid plaques was no longer statistically
significant (Table 4). In multivariable models, findings
were attenuated (Table 5). Interaction terms including
antihypertensive medications with night-time, daytime
and study systolic BPs, respectively, were included in the
models, but were not statistically significant (data not
shown).
Discussion
We have shown an association of night-time systolic BP
with two measures of subclinical cardiovascular disease,
GLS and carotid plaques, in a community-based middle-
aged population. These associations were attenuated in
multivariable models. No such associations were found
for daytime or study systolic BPs and subclinical cardio-
vascular disease.
Cumulative BP exposure over a 25-year period is asso-
ciated with subclinical systolic and diastolic dysfunction
assessed by speckle-tracking echocardiography in middle
age [39]. Uncontrolled 24-h BP has also been shown to be
associated with abnormal GLS, whereas uncontrolled
office BP was not, in treated hypertensive patients [40].
Few studies have specifically addressed the association of
night-time BP and GLS. Kalaycioglu et al. [22] found a
significant reduction in GLS in nondippers compared
with dippers in a sample of 86 treated hypertensive dia-
betic patients with a mean age of 57.8 years. They also
reported night-time systolic BP to be associated inde-
pendently with GLS and GLS rate in linear regression
models adjusted for age, sex and LV mass index [22]. In
untreated hypertensive patients, Tadic et al. [23] found
reduced two-dimensional and three-dimensional LV
GLS and reduced atrial longitudinal strain in nondippers
compared with dippers. Acar et al. [41] also examined LA
strain in dippers and nondippers and found reduced atrial
function in nondippers. Others have examined right heart
mechanics and found reduced function in nondippers
[42]. Our results suggest an association between
increased night-time systolic BP and subclinical LV sys-
tolic dysfunction. We also found night-time systolic BP to
have a stronger association than daytime systolic BP and
study BP with other echocardiographic markers of sub-
clinical cardiac damage such as LA volume and LV mass
(Supplementary Table 1, Supplemental digital content 1,
http://links.lww.com/BPMJ/A27).
CIMT does improve cardiovascular risk prediction
models, but the overall impact is small [43]. There are
concerns regarding measurement methods [44]. Moreover,
increasing IMT is recognized as a normal ageing phe-
nomenon that further complicates interpretation of CIMT
measurements [45–47]. The use of CIMT is therefore not
without controversy and therefore European and
American guidelines no longer recommend routine mea-
surement of CIMT in clinical practice for the assessment
of cardiovascular risk [48,49]. The addition of plaques has
been shown to improve the predictive performance of
CIMT [28,50]. Findings on the association of night-time
BP and CIMT are conflicting. Cuspidi et al. [10] reported
no difference in CIMT or plaques between those with
nocturnal normotension and nocturnal hypertension.
However, Wang et al. [51] reported an association between
Table 1 Baseline characteristics
Total cohort
(n=2047)
Sample with
satisfactory ABPM
(n=1072)
Sample
(n=50)
Age 59 ±6 60 ± 6 60 ±5
Male 1008 (49) 567 (47) 26 (52)
Education category
Primary 537 (28) 335 (30) 7 (15.5)
Secondary 936 (49) 547 (48) 22 (49)
Tertiary 435 (23) 253 (22) 16 (35.5)
IPAQ category
Low 932 (49) 571 (50) 31 (62)
Moderate 566 (30) 318 (28) 19 (38)
High 420 (22) 248 (22) 0 (0)
Smoking status
Nonsmoker 1002 (51) 615 (53) 27 (54)
Former smoker 671 (34) 378 (32) 18 (36)
Current smoker 292 (15) 175 (15) 5 (10)
Medical history
Hypertension 567 (29) 407 (34) 19 (40)
Myocardial infarction 49 (2) 33 (3) 2 (4)
Stroke 22 (1) 13 (1) 0 (0)
Heart failure 8 (0.4) 6 (0.5) 1 (2)
Diabetes 174 (9) 114 (10) 5 (10)
Medication
Antihypertensive 584 (29) 405 (35) 21 (42)
Cholesterol lowering 711 (36) 457 (39) 21 (42)
BMI (kg/m2) 29 ±5 30 ± 5 29 ±5
Waist circumference 97 ± 13 97 ±14 100 ±13
LDL (mmol/l) 3.2 ± 0.9 3.2 ±0.9 3.2 ±0.8
Creatinine (µmol/l) 71 ± 16 72 ±16 74 ±17
ACR (mg/mmol) 0.7 ± 2.1 0.8 ±2.1 0.6 ±0.7
eGFR (mls/min) 90 ±13 89 ±13 87 ±13
Cystatin C 0.83 ± 0.18 0.83 ±0.18 0.87 ±0.14
Study systolic 130 ±17 134 ± 18 134 ±16
Study diastolic 80 ±10 83 ±10 82 ±10
Daytime systolic – 131 ±14 132 ±12
Daytime diastolic – 77 ±9 78 ±9
Night-time systolic – 112 ±14 117 ±14
Night-time diastolic – 63 ±8 66 ±9
Twenty-four hour systolic – 124 ±13 126 ±11
Twenty-four hour diastolic – 72 ±8 74 ± 8
Note some missing data.
Values are given as mean ±SD or n (%).
ABPM, ambulatory blood pressure monitoring; ACR, albumin : creatinine ratio;
eGFR, estimated glomerular filtration rate; IPAQ, International Physical Activity
Questionnaire; LDL, low-density lipoprotein.
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nocturnal hypertension and CIMT in patients with
chronic kidney disease. Cuspidi et al. [52] have recently
reported the results of a meta-analysis that examined the
association of nondipping with carotid atherosclerosis and
found higher CIMT and greater prevalence of plaques in
nondippers. Although we found no association between
night-time systolic BP and CIMT, we did find an asso-
ciation with carotid plaques in univariable analysis. We
measured CIMT at the distal 1 cm of the common carotid
artery as the guidelines recommend, while we assessed all
of the extracranial carotid vessels for plaques [36]. This
may have contributed towards the differential findings for
CIMT and plaques as they likely reflect different stages of
atherosclerosis and plaques are more likely to develop in
areas of turbulent flow such as the bifurcation [53]. In
addition, we may not have had sufficient power to detect
an association between night-time BP and CIMT.
The evidence for the prognostic importance of night-
time BP is compelling [7]. However, the potential
underlying mechanisms are unclear and include altered
sympathetic nervous system activity, disturbed barore-
flex sensitivity, increased sodium sensitivity and
obstructive sleep apnoea [7]. It may be that night-time
BP is subject to less variability and more accurately
represents true BP [54]. Reverse causality is also possible
and elevated night-time BP may merely be a marker of
more severe end organ damage. Cuspidi and colleagues
have recently carried out a systematic review and meta-
analysis on the association of nocturnal hypertension with
subclinical cardiac and carotid disease documented by
ultrasound and found increased LV mass index and
CIMT in those with nocturnal hypertension compared
with those with nocturnal normotension [55]. They
acknowledge the cross-sectional nature of existing data
Table 2 Echocardiogram and carotid ultrasound characteristics
Total sample
(n=50) Normotension (n=11)
Isolated nocturnal
hypertension (n=14)
Isolated daytime
hypertension (n=14)
Sustained day–night
hypertension (n=11)
Echocardiogram
LA volume index (ml/m2) 32.0 ±9.4 27.7 ±7.3 32.6 ±9.7 31.3 ± 7.7 36.2 ±12.0*
LV mass index (g/m2) 99.3 ±24.2 85.5 ± 19.7 101.5 ±24.7 97.8 ±17.5 112.4 ±29.9*
Left ventricular hypertrophy 16 (32) 2 (18) 5 (36) 4 (29) 5 (45)
LV end diastolic volume
(ml/m2)
48.3 ±8.4 45.8 ±7.6 48.6 ±10.3 48.2 ±7.0 50.5 ±8.7
LV end systolic volume
(ml/m2)
17.2 ± 5.2 17.7 ± 6.8 17.5 ±7.0 16.3 ±2.9 17.6 ± 3.6
LV ejection fraction (%) 65.1 ±6.2 64.5 ± 7.2 64.9 ±7.5 66.0 ± 5.0 65.0 ±5.3
Global longitudinal strain (%) −21.2 ±3.0 −22.6 ± 2.9 −21.0 ±2.9 −21.9 ±2.8 −19.2 ±2.6*
Abnormal GLS 16 (33) 1 (10) 5 (36) 3 (21) 7 (64)
E/A 0.98 ±0.3 1.04 ±0.2 0.95 ±0.4 0.89 ± 0.2 1.05 ±0.3
E wave deceleration time
(ms)
253.9 ±74.2 224 ± 54 282 ±90.1 255.4 ±60.0 246 ±80.3
E′ (cm/s) 7.7 ±1.8 8.2 ± 1.0 7.3 ± 2.0 7.8 ± 2.2 7.9 ±1.6
E/e′ 9.5 ± 1.9 9.4 ± 0.9 9.9 ±1.9 8.6 ±2.1 10.2 ±2.3
Diastolic dysfunction 30 (60) 4 (36) 10 (71) 10 (71) 6 (55)
Carotid ultrasound
Common carotid IMT (mm) 0.72 ± 0.13 0.64 ±0.10 0.76 ±0.14* 0.71 ±0.14 0.76 ± 0.12*
Common carotid IMT>75th
percentile
12 (24) 1 (9) 4 (29) 3 (21) 4 (36)
Plaques 33 (66) 5 (45) 12 (86)* 8 (57) 8 (73)
GLS analysis not possible in one study because of poor image quality.
Values are given as mean ±SD or n (%).
GLS, global longitudinal strain; IMT, intima–media thickness; LA, left atrium; LV, left ventricle.
P values represent comparison with the normotensive group.
*P<0.05.
Table 3 Univariable linear and logistic regression results
GLS [β coefficients (95% CI)] P-value CIMT [β coefficient (95% CI)] P-value Plaques [OR (95% CI)] P-value
Sex (male vs. female) 2.70 (1.15–4.24) 0.001 0.09 (0.02–0.16) 0.02 6.5 (1.7–24.7) 0.006
Age 0.05 (−0.11–0.21) 0.5 0.009 (0.002–0.015) 0.009 1.2 (1.0–1.3) 0.03
Antihypertensives (yes vs. no) −0.91 (−2.65–0.84) 0.3 −0.03 (−0.11–0.05) 0.4 0.3 (0.1–1.1) 0.06
BMI 0.20 (0.03–0.37) 0.02 −0.004 (−001–0.004) 0.3 1.1 (0.96–1.2) 0.2
Smoking status (current vs. non/ex) −0.18 (−3.05–2.69) 0.9 0.18 (0.06–0.29) 0.004 2.2 (0.2–21.4) 0.5
Diabetes mellitus (yes vs. no) 3.16 (0.43–5.88) 0.02 0.02 (−0.11–0.15) 0.7 2.1 (0.2–20.9) 0.5
Total cholesterol 0.05 (−0.89–0.99) 0.9 −0.02 (−0.06–0.03) 0.4 0.67 (0.34–1.3) 0.2
Night-time SBP 0.85 (0.3–1.4) 0.003 0.02 (−0.002–0.05) 0.08 1.9 (1.1–3.2) 0.03
Daytime SBP 0.47 (−0.24–1.17) 0.2 0.02 (−0.01–0.05) 0.3 1.2 (0.7–2.0) 0.4
Study SBP 0.53 (0.01–1.06) 0.05 0.01 (−0.01–0.03) 0.4 1.16 (0.8–1.7) 0.4
β Coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg increase.
CI, confidence interval; CIMT, carotid intima–media thickness; GLS, global longitudinal strain; OR, odds ratio; SBP, systolic blood pressure.
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and that the causal relationship between nocturnal
hypertension and subclinical cardiovascular disease
remains unproven. Our study provides some prospective
data on subclinical target organ damage and our results
suggest that elevated night-time BP may contribute more
than daytime or office BP towards cardiac and vascular
end organ damage. However, large prospective rando-
mized trials with interventions aimed at normalizing
night-time BP are required to resolve the questions that
remain on the importance of night-time BP as a ther-
apeutic target. The methods of a large prospective open-
label blinded randomized-controlled trial have recently
been published, which may help to answer this question.
The treatment in morning versus evening trial aims to
randomize 10 269 hypertensive patients to either morn-
ing or evening dosing of antihypertensive medications.
The primary end-point is vascular death or hospitaliza-
tion for the composite of nonfatal myocardial infarction or
nonfatal stroke [56].
Limitations
This is a small study and the sample size may have
provided insufficient power to detect true associations
between night-time systolic BP and target organ damage
in multivariable models and for CIMT in particular. The
ultrasound machines used were in fulltime clinical use
and could only be used for research scans at the end of
the working day; therefore, collection of imaging data was
limited by access. This resulted in a prolonged data col-
lection period. Given these feasibility issues, a decision
was taken after 50 participants had been recruited to
proceed with data analysis. On the basis of our results, we
had 86% power to detect a true association between
night-time systolic BP and GLS. However, for CIMT, we
had just 33% power and would have required a sample
size of 162 to avoid a type II error [57].
Selection bias is another limitation as those who took part
in this study were more likely to self-report a history of
hypertension; therefore, the sample is not representative
of the full Mitchelstown Cohort (40 vs. 29% previous
doctor diagnosis of hypertension). Similarly, they were
more likely to report being on antihypertensive medica-
tion at baseline (42 vs. 29%). Also those who took part in
the study were better educated (35% had tertiary edu-
cation compared with 23% of the full cohort) and less
physically active (all of those taking part had low or
moderate physical activity levels and nobody had high
physical activity levels). In addition, the use of anti-
hypertensive medications in the sample increased
between 2010 and 2014 from 42% (n= 21) to 61%
(n=30), which may have impacted the results, although
one would expect that increased use of antihypertensive
medications would be more likely to influence results
towards the null hypothesis. Although interaction terms
did not suggest effect modification by antihypertensive
therapy, we repeated the univariable regression analysis
between night-time systolic BP and ultrasound markers
of subclinical cardiovascular disease by treatment status.
We found that the association between night-time sys-
tolic BP and subclinical cardiovascular disease was greater
for untreated individuals (data not shown). This needs to
Table 4 Sex-adjusted and age-adjusted linear and logistic regression results
GLS model 1
[β coefficient (95% CI)] P-value
GLS model 2
[β coefficient (95% CI)] P-value
GLS model 3
[β coefficient (95% CI)] P-value
Sex (male vs. female) 2.21 (0.64–3.77) 0.007 2.61 (0.89–4.33) 0.004 2.44 (0.64–4.23) 0.009
Age −0.0.5 (−0.20–0.10) 0.5 0.01 (−0.14–0.16) 0.9 0.002 (−0.15–0.15) 1.0
Night-time SBP 0.68 (0.11–1.25) 0.02 – – – –
Daytime SBP – – 0.08 (−0.61–0.78) 0.8 – –
Study SBP – – 0.17 (−0.40–0.74) 0.6
CIMT model 1
[β coefficient (95% CI)] P-value
CIMT model 2
[β coefficient (95% CI)] P-value
CIMT model 3
[β coefficient (95% CI)] P-value
Sex (male vs. female) 0.07 (−0.01–0.14) 0.07 0.07 (−0.01–0.14) 0.09 0.08 (−0.0003–0.16) 0.05
Age 0.01 (0.0001–0.01) 0.05 0.01 (0.001–0.01) 0.02 0.01 (0.001–0.01) 0.02
Night-time SBP 0.01 (−0.02–0.03) 0.6 – – – –
Daytime SBP – – 0.01 (−0.02–0.04) 0.6 – –
Study SBP – – – – −0.005 (−0.03–0.02) 0.7
Plaques model 1 [OR (95% CI)] P-value Plaques model 2 [OR (95% CI)] P-value Plaques model 3 [OR (95% CI)] P-value
Sex (male vs. female) 4.8 (1.16–19.86) 0.03 6.11 (1.39–26.75) 0.02 8.4 (1.64–43.01) 0.01
Age 1.11 (0.97–1.28) 0.1 1.14 (0.99–1.31) 0.06 1.15 (1.00–1.32) 0.05
Night-time SBP 1.47 (0.80–2.69) 0.2 – – – –
Daytime SBP – – 0.95 (0.55–1.65) 0.9 – –
Study SBP – – – – 0.80 (0.49–1.30) 0.4
β Coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg increase.
Model 1: night-time SBP adjusted for sex and age.
Model 2: daytime SBP adjusted for sex and age.
Model 3: study SBP adjusted for sex and age.
CI, confidence interval; CIMT, carotid intima–media thickness; GLS, global longitudinal strain; OR, odds ratio; SBP, systolic blood pressure.
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be interpreted with caution, given the small numbers
included in the analysis. However, future studies should
ideally recruit those who are not on antihypertensive
therapy. Although our study provides some prospective
imaging data in a community-based sample, the lack of
ultrasound data at baseline recruitment means that it is
not possible to draw inference on the temporal relation-
ship for the observed associations of night-time systolic
BP with GLS and carotid plaques.
In addition, night-time BP profiles are not fully repro-
ducible [58,59]. We could assess the reproducibility of BP
profiles in 47 of those who took part in this study. There
were no significant differences in the mean BP levels
between 2010 and 2014. However, the reproducibility of
dipping status was poor, with just 24% maintaining the
same profile after 4 years. The reproducibility of BP
profiles defined by the absolute BP level was better, but
still just 40% (Supplementary Tables 2–4, Supplemental
digital content 2, http://links.lww.com/BPMJ/A28). These
findings highlight the limitations of applying thresholds
and categories to continuously distributed risk factors but
also the need to be cautious when interpreting results of
studies examining nocturnal BP profiles on the basis of a
single ABPM recording.
The strength of this study lies in the novel question
addressed as limited studies have assessed the association
of night-time BP and GLS [22,23]. In addition, these
participants will continue to be followed up for the
Mitchelstown Cohort Study; thus, further prospective
data will be available over time.
Conclusion
This study suggests a trend towards an association
between night-time systolic BP with markers of sub-
clinical cardiac and vascular disease, although the sample
size limits interpretation of the multivariable analysis. We
did not find any significant association between these
markers and daytime systolic BP. When assessing ABPM
results, the absolute night-time BP seems to be a better
prognostic parameter than daytime systolic BP. However,
Table 5 Multivariable adjusted linear and logistic regression results
GLS model 1
[β coefficient (95% CI)] P-value
GLS model 2
[β coefficient (95% CI)] P-value
GLS model 3
[β coefficient (95% CI)] P-value
Sex (male vs. female) 1.79 (−0.03–3.6) 0.05 1.97 (0.03–3.9) 0.05 2.02 (0.03–4.01) 0.05
Age 0.002 (−0.17–0.17) 1.0 0.06 (−0.10–0.21) 0.5 0.06 (−0.10–0.22) 0.5
BMI 0.06 (−0.13–0.26) 0.5 0.11 (−0.08–0.30) 0.2 0.11 (−0.08–0.30) 0.2
Smoking (current vs. non/ex) −0.01 (−2.82–2.80) 1.0 0.27 (−2.61–3.15) 0.9 0.28 (−2.60–3.16) 0.8
Diabetes mellitus (yes vs. no) 1.91 (−0.75–4.56) 0.2 2.16 (−0.57–4.89) 0.1 2.16 (−0.61–4.93) 0.1
Total cholesterol 0.28 (−0.62–1.17) 0.5 0.38 (−0.54–1.29) 0.4 0.38 (−0.54–1.31) 0.4
Night-time SBP 0.52 (−0.13–1.16) 0.1 – – – –
Daytime SBP – – 0.04 (−0.66–0.75) 0.9 – –
Study SBP – – – – −0.01 (−0.61–0.58) 1.0
CIMT model 1
[β coefficient (95% CI)] P-value
CIMT model 2
[β coefficient (95% CI)] P-value
CIMT model 3
[β coefficient (95% CI)] P-value
Sex (male vs. female) 0.07 (−0.01–0.15) 0.07 0.07 (−0.01–0.15) 0.1 0.07 (−0.01–0.16) 0.08
Age 0.01 (−0.001–0.01) 0.08 0.01 (0.004–0.01) 0.04 0.01 (0.0003–0.1) 0.04
BMI −0.003 (−0.01–0.004) 0.4 −0.003 (−0.01–0.004) 0.4 −0.0.003 (−0.01–0.004) 0.5
Smoking (current vs.
non/ex)
0.15 (0.03–0.27) 0.02 0.16 (0.04–0.28) 0.01 0.16 (0.04–0.28) 0.01
Diabetes mellitus (yes
vs. no)
0.02 (−0.10–0.13) 0.8 0.02 (−0.09–0.14) 0.7 0.02 (−0.10–0.14) 0.7
Total cholesterol −0.01 (−0.05–0.03) 0.5 −0.01 (−0.05–0.03) 0.6 −0.01 (−0.05–0.03) 0.6
Night-time SBP 0.01 (−0.02–0.03) 0.5 – – – –
Daytime SBP – – 0.01 (−0.02–0.04) 0.5 – –
Study SBP – – – – 0.001 (−0.02–0.95) 0.2
Plaques model 1 [OR (95% CI)] P-value Plaques model 2 [OR (95% CI)] P-value Plaques model 3 [OR (95% CI)] P-value
Sex (male vs. female) 4.66 (0.78–27.80) 0.09 5.70 (0.84–38.50) 0.07 6.57 (0.93–46.49) 0.06
Age 1.17 (0.99–1.38) 0.07 1.19 (1.01–1.40) 0.03 1.21 (1.02–1.42) 0.03
BMI 1.10 (0.93–1.30) 0.3 1.13 (0.95–1.33) 0.2 1.13 (0.96–1.34) 0.1
Smoking (current vs. non/ex) 6.81 (0.30–157.32) 0.2 10.28 (0.38–280.48) 0.2 9.16 (0.39–217.16) 0.2
Diabetes mellitus (yes vs. no) 0.61 (0.04–10.57) 0.7 0.74 (0.04–12.38) 0.8 0.93 (0.05–16.23) 1.0
Total cholesterol 0.63 (0.25–1.56) 0.3 0.69 (0.29–1.64) 0.4 0.70 (0.29–1.70) 0.4
Night-time SBP 1.31 (0.65–2.66) 0.5 – – – –
Daytime SBP – – 0.86 (0.46–1.62) 0.6 – –
Study SBP – – – – 0.78 (0.45–1.37) 0.4
β Coefficients and odds ratios for night-time SBP, daytime SBP and study SBP represent per 10 mmHg increase.
Model 1: night-time SBP adjusted for sex, age, BMI, smoking, diabetes mellitus and total cholesterol.
Model 2: daytime SBP adjusted for sex, age, BMI, smoking, diabetes mellitus and total cholesterol.
Model 3: study SBP adjusted for sex, age, BMI, smoking, diabetes mellitus and total cholesterol.
CI, confidence interval; CIMT, carotid intima–media thickness; GLS, global longitudinal strain; OR, odds ratio; SBP, systolic blood pressure.
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whether normalizing night-time BP improves prognosis
remains unanswered and only a large randomized-
controlled trial involving chronotherapy can address this.
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